文献速递慢性静脉疾病

热消融与非热消融腔内治疗方案有效性与安全性的网状Meta分析

A network meta-analysis on the efficacy and safety of thermal and nonthermal endovenous ablation treatments.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-04-06

该研究按照PRISMA声明开展系统评价与贝叶斯网状Meta分析,纳入14项研究、4177例患者,平均随访25.7个月,评估热消融与非热消融腔内治疗下肢浅静脉功能不全的中期有效性与安全性。结果显示,与机械化学消融(MOCA)相比,射频消融(RFA)、氰基丙烯酸酯消融(CAC)和腔内激光消融(EVLA)的大隐静脉(GSV)闭合优势比升高;MOCA在静脉临床严重程度评分(VCSS)改善方面劣于RFA、EVLA和CAC;EVLA术后感觉异常风险高于MOCA、CAC和RFA。

要点

  • 与MOCA相比,RFA、CAC和EVLA的GSV闭合优势比升高。
  • MOCA在VCSS改善方面劣于RFA、EVLA和CAC。
  • EVLA术后感觉异常风险高于MOCA、CAC和RFA。

核心结论

  • 分析结果对MOCA中期VCSS改善和GSV闭合率方面的有效性产生质疑,而CAC与RFA和EVLA相比显示等效结果。
  • 与EVLA相比,CAC术后感觉异常、色素沉着和硬结风险降低。
  • RFA和CAC相比1470 nm EVLA具有更好的疼痛特征。
  • 非热、非肿胀消融方式在消融大GSV方面可能表现不佳,需要进一步研究。

研究设计与样本

  • 按照PRISMA声明开展系统评价与贝叶斯网状Meta分析。
  • 纳入14项研究、4177例患者,平均随访25.7个月。
  • 主要终点为GSV闭合和VCSS改善,并以GSV直径作为协变量对两个主要终点进行Meta回归。

主要发现

  • 与MOCA相比,RFA(OR 3.99,95%CI 1.82-10.53)、CAC(OR 3.09,95%CI 1.35-8.37)和EVLA(OR 2.72,95%CI 1.23-7.38)的GSV闭合优势比升高。
  • MOCA在VCSS改善方面劣于RFA(MD 0.96,95%CI 0.71-1.20)、EVLA(MD 0.94,95%CI 0.61-1.24)和CAC(MD 0.89,95%CI 0.65-1.15)。
  • EVLA术后感觉异常风险高于MOCA(RR 9.61,95%CI 2.32-62.29)、CAC(RR 7.90,95%CI 2.44-38.16)和RFA(RR 6.96,95%CI 2.31-28.04)。
  • 总体分析中Aberdeen静脉曲张问卷评分改善、血栓性静脉炎、瘀斑和疼痛的差异未达统计学显著。
  • 1470 nm EVLA的疼痛评分高于RFA(MD 3.22,95%CI 0.93-5.47)和CAC(MD 3.04,95%CI 1.05-4.97)。

关键数值与推荐

  • 敏感性分析显示MOCA在GSV闭合方面持续劣于RFA(OR 4.33,95%CI 1.15-55.54)。
  • 敏感性分析显示MOCA在VCSS改善方面持续劣于RFA(MD 0.99,95%CI 0.22-1.77)和CAC(MD 0.84,95%CI 0.08-1.65)。
  • GSV闭合回归模型未达统计学显著,但显示CAC和MOCA在大GSV直径下相比RFA和EVLA有效性有下降趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • GSV闭合回归模型未达统计学显著,仅显示趋势。
  • 非热、非肿胀消融方式在大GSV消融方面可能表现不佳,需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed the mid-term efficacy and safety of thermal and nonthermal endovenous ablation for the treatment of lower limb superficial venous insufficiency. METHODS: We performed a systematic review in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement and a Bayesian network meta-analysis. The primary end points were great saphenous vein (GSV) closure and venous clinical severity score (VCSS) improvement. A meta-regression using GSV diameter as a covariate was undertaken for the two primary end points. RESULTS: We included 14 studies and 4177 patients, with a mean follow-up of 25.7 months. Radiofrequency ablation (RFA; odds ratio [OR], 3.99; 95% confidence interval [CI], 1.82-10.53), cyanoacrylate ablation (CAC; OR, 3.09; 95% CI, 1.35-8.37), and endovenous laser ablation (EVLA; OR, 2.72; 95% CI, 1.23-7.38) displayed increased odds for GSV closure compared with mechanochemical ablation (MOCA). MOCA inferiority compared with RFA (mean difference [MD], 0.96; 95% CI, 0.71-1.20), EVLA (MD, 0.94; 95% CI, 0.61-1.24), and CAC (MD, 0.89; 95% CI, 0.65-1.15) was also depicted regarding VCSS improvement. EVLA resulted in an increased risk of postoperative paresthesia compared with MOCA (risk ratio [RR], 9.61; 95% CI, 2.32-62.29), CAC (RR, 7.90; 95% CI, 2.44-38.16), and RFA (RR, 6.96; 95% CI, 2.31-28.04). Although the overall analysis identified nonstatistically significant differences for Aberdeen varicose vein questionnaire score improvement, thrombophlebitis, ecchymosis, and pain, further investigation revealed an increase pain profile for EVLA at 1470 nm compared with RFA (MD, 3.22; 95% CI, 0.93-5.47) and CAC (MD, 3.04; 95% CI, 1.05-4.97). A sensitivity analysis displayed a persistent underperformance of MOCA compared with RFA (OR, 4.33; 95% CI, 1.15-55.54) for GSV closure and both RFA (MD, 0.99; 95% CI, 0.22-1.77) and CAC (MD, 0.84; 95% CI, 0.08-1.65) regarding VCCS improvement. Although no regression model reached statistical significance, the GSV closure regression model revealed a trend for considerably decreased efficacy for both CAC and MOCA with larger GSV diameters compared with RFA and EVLA. CONCLUSIONS: Although our analysis has produced skepticism regarding the efficacy of MOCA in the mid-term period for VCSS improvement and GSV closure rates, CAC showed equivalent results compared with both RFA and EVLA. Additionally, CAC displayed a decreased risk of postprocedural paresthesia and pigmentation and induration compared with EVLA. Also, both RFA and CAC had an improved pain profile compared with EVLA 1470 nm. The potential underperformance of nonthermal, nontumescent ablation modalities in ablating large GSVs necessitates further research.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Bontinis V, Bontinis A, Koutsoumpelis A, et al. A network meta-analysis on the efficacy and safety of thermal and nonthermal endovenous ablation treatments. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37030442. doi:10.1016/j.jvsv.2023.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。